Genetic disruption of 2-arachidonoylglycerol synthesis reveals a key role for endocannabinoid signaling in anxiety modulation.

[1]  Masahiko Watanabe,et al.  Multiple Mechanistically Distinct Modes of Endocannabinoid Mobilization at Central Amygdala Glutamatergic Synapses , 2014, Neuron.

[2]  J. Long,et al.  Monoacylglycerol Lipase Inhibition Blocks Chronic Stress-Induced Depressive-Like Behaviors via Activation of mTOR Signaling , 2014, Neuropsychopharmacology.

[3]  S. Galea,et al.  Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks , 2013, Psychoneuroendocrinology.

[4]  Sachin Patel,et al.  Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses , 2013, Biology of Mood & Anxiety Disorders.

[5]  Sachin Patel,et al.  Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation , 2013, Nature Neuroscience.

[6]  H. Pape,et al.  Cannabinoid CB1 Receptor in Dorsal Telencephalic Glutamatergic Neurons: Distinctive Sufficiency for Hippocampus-Dependent and Amygdala-Dependent Synaptic and Behavioral Functions , 2013, The Journal of Neuroscience.

[7]  Sachin Patel,et al.  Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice , 2013, Psychopharmacology.

[8]  B. Lutz,et al.  Biphasic Effects of Cannabinoids in Anxiety Responses: CB1 and GABAB Receptors in the Balance of GABAergic and Glutamatergic Neurotransmission , 2012, Neuropsychopharmacology.

[9]  J. Copeland,et al.  The association between distress tolerance and cannabis use-related problems: the mediating and moderating roles of coping motives and gender. , 2012, Addictive behaviors.

[10]  M. Kano,et al.  Endocannabinoids and Retrograde Modulation of Synaptic Transmission , 2012, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[11]  M. Häring,et al.  Neuronal populations mediating the effects of endocannabinoids on stress and emotionality , 2012, Neuroscience.

[12]  B. Lutz,et al.  The endocannabinoid system in anxiety, fear memory and habituation , 2012, Journal of psychopharmacology.

[13]  Sachin Patel,et al.  Reversible Gating of Endocannabinoid Plasticity in the Amygdala by Chronic Stress: A Potential Role for Monoacylglycerol Lipase Inhibition in the Prevention of Stress-Induced Behavioral Adaptation , 2011, Neuropsychopharmacology.

[14]  G. González-Burgos,et al.  Postsynaptic diacylglycerol lipase α mediates retrograde endocannabinoid suppression of inhibition in mouse prefrontal cortex , 2011, The Journal of physiology.

[15]  A. Hohmann,et al.  Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. , 2011, Pharmacological research.

[16]  R. Stephens,et al.  Motives for cannabis use in high-risk adolescent users. , 2011, Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors.

[17]  A. Pastor,et al.  Differential Role of Anandamide and 2-Arachidonoylglycerol in Memory and Anxiety-like Responses , 2011, Biological Psychiatry.

[18]  Masahiko Watanabe,et al.  Unique inhibitory synapse with particularly rich endocannabinoid signaling machinery on pyramidal neurons in basal amygdaloid nucleus , 2011, Proceedings of the National Academy of Sciences.

[19]  J. Bains,et al.  Functional Interactions between Stress and the Endocannabinoid System: From Synaptic Signaling to Behavioral Output , 2010, The Journal of Neuroscience.

[20]  T. Cassano,et al.  Genetic Deletion of Fatty Acid Amide Hydrolase Alters Emotional Behavior and Serotonergic Transmission in the Dorsal Raphe, Prefrontal Cortex, and Hippocampus , 2010, Neuropsychopharmacology.

[21]  D. Centonze,et al.  Preservation of Striatal Cannabinoid CB1 Receptor Function Correlates with the Antianxiety Effects of Fatty Acid Amide Hydrolase Inhibition , 2010, Molecular Pharmacology.

[22]  Masahiko Watanabe,et al.  The Endocannabinoid 2-Arachidonoylglycerol Produced by Diacylglycerol Lipase α Mediates Retrograde Suppression of Synaptic Transmission , 2010, Neuron.

[23]  M. Pangalos,et al.  Loss of Retrograde Endocannabinoid Signaling and Reduced Adult Neurogenesis in Diacylglycerol Lipase Knock-out Mice , 2010, The Journal of Neuroscience.

[24]  R. Mangieri,et al.  The endocannabinoid system as a target for the treatment of cannabis dependence , 2009, Neuropharmacology.

[25]  R. Sinha,et al.  Stress-related factors in cannabis use and misuse: implications for prevention and treatment. , 2009, Journal of substance abuse treatment.

[26]  Bruce S. McEwen,et al.  Stress, memory and the amygdala , 2009, Nature Reviews Neuroscience.

[27]  B. Lutz,et al.  Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[28]  B. Lutz.  Endocannabinoid signals in the control of emotion. , 2009, Current opinion in pharmacology.

[29]  Benjamin F. Cravatt,et al.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects , 2008, Nature chemical biology.

[30]  C. Hillard,et al.  Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation , 2008, The European journal of neuroscience.

[31]  Ethan B. Russo.  Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? , 2008, Neuro endocrinology letters.

[32]  B. Gorzalka,et al.  Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report. , 2008, Pharmacopsychiatry.

[33]  B. Lutz,et al.  Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors , 2008, Neuropharmacology.

[34]  Robin Christensen,et al.  Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials , 2007, The Lancet.

[35]  A. Etkin,et al.  Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia. , 2007, The American journal of psychiatry.

[36]  M. Zvolensky,et al.  Marijuana use motives and social anxiety among marijuana-using young adults. , 2007, Addictive behaviors.

[37]  K. Mackie,et al.  A Key Role for Diacylglycerol Lipase-α in Metabotropic Glutamate Receptor-Dependent Endocannabinoid Mobilization , 2007, Molecular Pharmacology.

[38]  C. Hillard,et al.  Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling , 2006, Journal of Pharmacology and Experimental Therapeutics.

[39]  A. Schierloh,et al.  Cannabinoid Receptor Type 1 Located on Presynaptic Terminals of Principal Neurons in the Forebrain Controls Glutamatergic Synaptic Transmission , 2006, The Journal of Neuroscience.

[40]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  S. File,et al.  Endocannabinoid system and stress and anxiety responses , 2005, Pharmacology Biochemistry and Behavior.

[42]  K. Carey,et al.  Relations between cannabis use and dependence, motives for cannabis use and anxious, depressive and borderline symptomatology. , 2005, Addictive behaviors.

[43]  B. Gorzalka,et al.  Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. , 2004, European journal of pharmacology.

[44]  D. Piomelli.  The molecular logic of endocannabinoid signalling , 2003, Nature Reviews Neuroscience.

[45]  Beat Lutz,et al.  Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. , 2003, Learning & memory.

[46]  B. Alger.  Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids , 2002, Progress in Neurobiology.

[47]  T. Freund,et al.  Brain monoglyceride lipase participating in endocannabinoid inactivation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Hall,et al.  Long-term cannabis use: characteristics of users in an Australian rural area. , 1998, Addiction.

[49]  Masahiko Watanabe,et al.  Endocannabinoid-mediated control of synaptic transmission. , 2009, Physiological reviews.

[50]  S. Gaetani,et al.  Modulation of anxiety through blockade of anandamide hydrolysis , 2003, Nature Medicine.

[51]  W. Drevets,et al.  Differentiating primary pathophysiologic from secondary adaptational processes , 2001, Depression and anxiety.